---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-23-000034"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:55:00.634856+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas reports EDIT-301 (reni-cel) data: all 11 SCD patients free of vaso-occlusive events

## Summary
- All 11 SCD patients in RUBY trial free of vaso-occlusive events post reni-cel; 6 with >=5 months follow-up achieved normal Hb and >40% fetal Hb.
- 6 TDT patients in EdiTHAL trial showed early robust total hemoglobin rise above 9 g/dL transfusion independence threshold.
- Reni-cel well-tolerated in all 17 patients; safety profile consistent with myeloablative conditioning; no SAEs related to reni-cel reported.
- Data presented at ASH and company webinar; additional dosing and further updates expected mid-2024.

## SEC filing metadata
- accession: 0001650664-23-000034
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000034/0001650664-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000034/edit-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-23-000034
- JSON: https://secwatch.observer/filing/0001650664-23-000034.json
- Plain text: https://secwatch.observer/filing/0001650664-23-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.